Septerna is a clinical stage biotech company developing oral small molecule medicines that target G protein coupled receptors. SEPN reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | JP Morgan | Maintained | Buy | |
| Aug 13 | Jones Trading | Maintained | Buy | |
| Aug 12 | Wells Fargo | Maintained | Buy | |
| Aug 12 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 11 | Guggenheim | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in SEPN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SEPN is in one of them and how their past SEPN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SEPN in an article yet. Here's the latest on the wider market.
About Septerna
Septerna is a clinical stage biotechnology company based in South San Francisco, California. It uses its Native Complex Platform to discover oral small molecule medicines that act on G protein coupled receptors, a large family of proteins that help control many processes in the body. Its pipeline is focused on endocrine diseases, immune and inflammatory conditions, and metabolic diseases. The company aims to develop these medicines for patients with significant unmet medical needs.
- Headquarters
- South San Francisco, CA